Factors associated with expression of extrapyramidal symptoms in users of atypical antipsychotics
Autor(a) principal: | |
---|---|
Data de Publicação: | 2016 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFRN |
Texto Completo: | https://repositorio.ufrn.br/jspui/handle/123456789/25430 http://dx.doi.org/10.1007/s00228-016-2166-2 |
Resumo: | Purpose The aim of this study was to investigate factors associated with the occurrence of extrapyramidal symptoms (EPS) in users of second-generation antipsychotics (SGA). Methods Observational cross-sectional study based on a random sample of subjects from three outpatient clinics. Inclusion criteria were age between 18 and 65 years, of both genders, with a diagnosis of schizophrenia and under the use of a single SGA agent. Subjects who had received i.m. long-acting antipsychotics in the past were excluded. The families of eligible patients were contacted by phone and, if willing to participate in the study, a household visit was scheduled. Informed consent was obtained from all study subjects and their next of kin. The risk of EPS associated with sociodemographic, clinical features and medications used was analyzed by logistic regression. Results The study population consisted of 213 subjects. EPS were observed in 38.0% of subjects. The more commonly used SGA were olanzapine (76, 35.7%), risperidone (74, 34.3%), quetiapine (26, 12.2%), and ziprasidone (23, 10.8%). Among the drugs used as adjunctive therapy for schizophrenia, benzodiazepines were the most prevalent (31.5%), followed by carbamazepine (24.4%) and antidepressants (20.2%). Multivariate analysis showed that the risk of EPS was associated with the use of carbamazepine (odds ratio 3.677, 95% CI 1.627–8.310). We found no evidence that the type of SGA modified the risk of EPS. Conclusion The occurrence of EPS in SGA users is a common finding, with no difference of antipsychotics studied in relation to the risk of extrapyramidal manifestations. The adjunctive use of carbamazepine may predispose the user of SGA to the occurrence of EPS. |
id |
UFRN_5b18a74f51964f7a476140743c2e6842 |
---|---|
oai_identifier_str |
oai:https://repositorio.ufrn.br:123456789/25430 |
network_acronym_str |
UFRN |
network_name_str |
Repositório Institucional da UFRN |
repository_id_str |
|
spelling |
Araújo, Aurigena Antunes deRibeiro, Susana BarbosaMedeiros, Caroline Addison XavierChaves, Katarina MeloAlves, Maria do Socorro Costa FeitosaOliveira, Antonio GouveiaMartins, Rand Randall2018-06-16T12:50:43Z2018-06-16T12:50:43Z2016-11-26ARAÚJO, Aurigena Antunes de et al. Factors associated with expression of extrapyramidal symptoms in users of atypical antipsychotics. European Journal of Clinical Pharmacology, v. 73, p. 351-355, 2016. Disponível em: <https://link.springer.com/article/10.1007/s00228-016-2166-2>. Acesso em: 20 mar. 2018.1432-1041https://repositorio.ufrn.br/jspui/handle/123456789/25430http://dx.doi.org/10.1007/s00228-016-2166-2engSpringer Berlin HeidelbergSchizophreniaSecond-generation antipsychoticsExtrapyramidal symptomsAdjunctive therapyFactors associated with expression of extrapyramidal symptoms in users of atypical antipsychoticsinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlePurpose The aim of this study was to investigate factors associated with the occurrence of extrapyramidal symptoms (EPS) in users of second-generation antipsychotics (SGA). Methods Observational cross-sectional study based on a random sample of subjects from three outpatient clinics. Inclusion criteria were age between 18 and 65 years, of both genders, with a diagnosis of schizophrenia and under the use of a single SGA agent. Subjects who had received i.m. long-acting antipsychotics in the past were excluded. The families of eligible patients were contacted by phone and, if willing to participate in the study, a household visit was scheduled. Informed consent was obtained from all study subjects and their next of kin. The risk of EPS associated with sociodemographic, clinical features and medications used was analyzed by logistic regression. Results The study population consisted of 213 subjects. EPS were observed in 38.0% of subjects. The more commonly used SGA were olanzapine (76, 35.7%), risperidone (74, 34.3%), quetiapine (26, 12.2%), and ziprasidone (23, 10.8%). Among the drugs used as adjunctive therapy for schizophrenia, benzodiazepines were the most prevalent (31.5%), followed by carbamazepine (24.4%) and antidepressants (20.2%). Multivariate analysis showed that the risk of EPS was associated with the use of carbamazepine (odds ratio 3.677, 95% CI 1.627–8.310). We found no evidence that the type of SGA modified the risk of EPS. Conclusion The occurrence of EPS in SGA users is a common finding, with no difference of antipsychotics studied in relation to the risk of extrapyramidal manifestations. The adjunctive use of carbamazepine may predispose the user of SGA to the occurrence of EPS.info:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRNinstname:Universidade Federal do Rio Grande do Norte (UFRN)instacron:UFRNTEXTFactors associated with expression of extrapyramidal _2016.pdf.txtFactors associated with expression of extrapyramidal _2016.pdf.txtExtracted texttext/plain24160https://repositorio.ufrn.br/bitstream/123456789/25430/3/Factors%20associated%20with%20expression%20of%20extrapyramidal%20_2016.pdf.txtb3f15a99e1ff507487e12f20920cd18dMD53THUMBNAILFactors associated with expression of extrapyramidal _2016.pdf.jpgFactors associated with expression of extrapyramidal _2016.pdf.jpgIM Thumbnailimage/jpeg8019https://repositorio.ufrn.br/bitstream/123456789/25430/4/Factors%20associated%20with%20expression%20of%20extrapyramidal%20_2016.pdf.jpg91b108f6c265f04e8094257364bd0580MD54ORIGINALFactorsAssociatedExpression_Araujo_2016.pdfFactorsAssociatedExpression_Araujo_2016.pdfapplication/pdf251534https://repositorio.ufrn.br/bitstream/123456789/25430/1/FactorsAssociatedExpression_Araujo_2016.pdf188f1409d79a398b811c88f9fc94b6a0MD51LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://repositorio.ufrn.br/bitstream/123456789/25430/2/license.txt8a4605be74aa9ea9d79846c1fba20a33MD52123456789/254302021-11-11 16:14:01.796oai:https://repositorio.ufrn.br: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Repositório de PublicaçõesPUBhttp://repositorio.ufrn.br/oai/opendoar:2021-11-11T19:14:01Repositório Institucional da UFRN - Universidade Federal do Rio Grande do Norte (UFRN)false |
dc.title.pt_BR.fl_str_mv |
Factors associated with expression of extrapyramidal symptoms in users of atypical antipsychotics |
title |
Factors associated with expression of extrapyramidal symptoms in users of atypical antipsychotics |
spellingShingle |
Factors associated with expression of extrapyramidal symptoms in users of atypical antipsychotics Araújo, Aurigena Antunes de Schizophrenia Second-generation antipsychotics Extrapyramidal symptoms Adjunctive therapy |
title_short |
Factors associated with expression of extrapyramidal symptoms in users of atypical antipsychotics |
title_full |
Factors associated with expression of extrapyramidal symptoms in users of atypical antipsychotics |
title_fullStr |
Factors associated with expression of extrapyramidal symptoms in users of atypical antipsychotics |
title_full_unstemmed |
Factors associated with expression of extrapyramidal symptoms in users of atypical antipsychotics |
title_sort |
Factors associated with expression of extrapyramidal symptoms in users of atypical antipsychotics |
author |
Araújo, Aurigena Antunes de |
author_facet |
Araújo, Aurigena Antunes de Ribeiro, Susana Barbosa Medeiros, Caroline Addison Xavier Chaves, Katarina Melo Alves, Maria do Socorro Costa Feitosa Oliveira, Antonio Gouveia Martins, Rand Randall |
author_role |
author |
author2 |
Ribeiro, Susana Barbosa Medeiros, Caroline Addison Xavier Chaves, Katarina Melo Alves, Maria do Socorro Costa Feitosa Oliveira, Antonio Gouveia Martins, Rand Randall |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Araújo, Aurigena Antunes de Ribeiro, Susana Barbosa Medeiros, Caroline Addison Xavier Chaves, Katarina Melo Alves, Maria do Socorro Costa Feitosa Oliveira, Antonio Gouveia Martins, Rand Randall |
dc.subject.por.fl_str_mv |
Schizophrenia Second-generation antipsychotics Extrapyramidal symptoms Adjunctive therapy |
topic |
Schizophrenia Second-generation antipsychotics Extrapyramidal symptoms Adjunctive therapy |
description |
Purpose The aim of this study was to investigate factors associated with the occurrence of extrapyramidal symptoms (EPS) in users of second-generation antipsychotics (SGA). Methods Observational cross-sectional study based on a random sample of subjects from three outpatient clinics. Inclusion criteria were age between 18 and 65 years, of both genders, with a diagnosis of schizophrenia and under the use of a single SGA agent. Subjects who had received i.m. long-acting antipsychotics in the past were excluded. The families of eligible patients were contacted by phone and, if willing to participate in the study, a household visit was scheduled. Informed consent was obtained from all study subjects and their next of kin. The risk of EPS associated with sociodemographic, clinical features and medications used was analyzed by logistic regression. Results The study population consisted of 213 subjects. EPS were observed in 38.0% of subjects. The more commonly used SGA were olanzapine (76, 35.7%), risperidone (74, 34.3%), quetiapine (26, 12.2%), and ziprasidone (23, 10.8%). Among the drugs used as adjunctive therapy for schizophrenia, benzodiazepines were the most prevalent (31.5%), followed by carbamazepine (24.4%) and antidepressants (20.2%). Multivariate analysis showed that the risk of EPS was associated with the use of carbamazepine (odds ratio 3.677, 95% CI 1.627–8.310). We found no evidence that the type of SGA modified the risk of EPS. Conclusion The occurrence of EPS in SGA users is a common finding, with no difference of antipsychotics studied in relation to the risk of extrapyramidal manifestations. The adjunctive use of carbamazepine may predispose the user of SGA to the occurrence of EPS. |
publishDate |
2016 |
dc.date.issued.fl_str_mv |
2016-11-26 |
dc.date.accessioned.fl_str_mv |
2018-06-16T12:50:43Z |
dc.date.available.fl_str_mv |
2018-06-16T12:50:43Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
ARAÚJO, Aurigena Antunes de et al. Factors associated with expression of extrapyramidal symptoms in users of atypical antipsychotics. European Journal of Clinical Pharmacology, v. 73, p. 351-355, 2016. Disponível em: <https://link.springer.com/article/10.1007/s00228-016-2166-2>. Acesso em: 20 mar. 2018. |
dc.identifier.uri.fl_str_mv |
https://repositorio.ufrn.br/jspui/handle/123456789/25430 |
dc.identifier.issn.none.fl_str_mv |
1432-1041 |
dc.identifier.doi.none.fl_str_mv |
http://dx.doi.org/10.1007/s00228-016-2166-2 |
identifier_str_mv |
ARAÚJO, Aurigena Antunes de et al. Factors associated with expression of extrapyramidal symptoms in users of atypical antipsychotics. European Journal of Clinical Pharmacology, v. 73, p. 351-355, 2016. Disponível em: <https://link.springer.com/article/10.1007/s00228-016-2166-2>. Acesso em: 20 mar. 2018. 1432-1041 |
url |
https://repositorio.ufrn.br/jspui/handle/123456789/25430 http://dx.doi.org/10.1007/s00228-016-2166-2 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Springer Berlin Heidelberg |
publisher.none.fl_str_mv |
Springer Berlin Heidelberg |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFRN instname:Universidade Federal do Rio Grande do Norte (UFRN) instacron:UFRN |
instname_str |
Universidade Federal do Rio Grande do Norte (UFRN) |
instacron_str |
UFRN |
institution |
UFRN |
reponame_str |
Repositório Institucional da UFRN |
collection |
Repositório Institucional da UFRN |
bitstream.url.fl_str_mv |
https://repositorio.ufrn.br/bitstream/123456789/25430/3/Factors%20associated%20with%20expression%20of%20extrapyramidal%20_2016.pdf.txt https://repositorio.ufrn.br/bitstream/123456789/25430/4/Factors%20associated%20with%20expression%20of%20extrapyramidal%20_2016.pdf.jpg https://repositorio.ufrn.br/bitstream/123456789/25430/1/FactorsAssociatedExpression_Araujo_2016.pdf https://repositorio.ufrn.br/bitstream/123456789/25430/2/license.txt |
bitstream.checksum.fl_str_mv |
b3f15a99e1ff507487e12f20920cd18d 91b108f6c265f04e8094257364bd0580 188f1409d79a398b811c88f9fc94b6a0 8a4605be74aa9ea9d79846c1fba20a33 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFRN - Universidade Federal do Rio Grande do Norte (UFRN) |
repository.mail.fl_str_mv |
|
_version_ |
1797776973727006720 |